Clinical Trial Update: Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating meta-iodobenzylguanidine (123I mIBG) scintigraphy in patients being evaluated for pheochromocytoma or neuroblastoma has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Pheochromocytoma

Drugs mentioned

• meta-iodobenzylguanidine (123I mIBG) (meta-iodobenzylguanidine (123I mIBG))

Snippet

Sponsor: GE Healthcare | Conditions: Pheochromocytoma, Neuroblastoma | Phase 3 | Status: COMPLETED